Saccharomyces boulardii and C. difficile

What 2 graded rows on saccharomyces boulardii agree on for C. difficile, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Saccharomyces boulardii page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Saccharomyces boulardii page, with its PubMed record.

Supplement

Saccharomyces boulardii Choose another

2 rows · 244 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade D, is a randomized trial of 124 people (1994) and found an improvement.

The rows run from 120 to 124 people, published from 1994 to 2025: 2 single studies.

2 improved

Grade DRecurrence of C. difficile disease (add-on to vancomycin or metronidazole) · Improved
RCT · n 124 · 1994 · Adults with active C. difficile disease (64 first episode, 60 recurrent); people immunosuppressed by AIDS or recent chemotherapy excluded
1 g/day · 4 weeks, plus 4 weeks of follow-up
Recurrence was lower overall (RR 0.43, 95% CI 0.20–0.97). The benefit was significant in people with recurrent disease (34.6% vs 64.7%) but not after a first episode (19.3% vs 24.2%). No serious adverse reactions.
Row on the Saccharomyces boulardii page · PubMed 8201735 (opens PubMed)
Grade DRecurrence of C. difficile infection (add-on to vancomycin) · Improved
RCT · n 120 · 2025 · Hospitalized adults with mild to moderate C. difficile infection (Thailand)
500 mg every 12 hours (two 250 mg capsules) · 10 days
Clinical success was similar (98.4% vs 98.3%), but recurrence was lower (1.7% vs 13.1%, p = 0.032) and overall success higher (96.6% vs 85.3%) than with placebo; adverse events did not differ.
Row on the Saccharomyces boulardii page · PubMed 40457042 (opens PubMed)